Harmony Biosciences
$42.25
106
+$0.39+0.93% Friday 20:00
+$0.27+0.64%Friday 23:59After hours
Statistics
Day High
42.25
Day Low
42.17
52W High
43.49
52W Low
25.52
Volume
30,342
Avg. Volume
-
Mkt Cap
2.46B
P/E Ratio
14.85
Dividend Yield
-
Dividend
-
Upcoming
Earnings
3NovExpected
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Q2 2026
Next
0.55
0.79
1.04
1.28
Expected EPS
1.107739
Actual EPS
N/A
Financials
18.27%Profit Margin
Profitable868.45MRevenue
158.69MNet Income
Analyst Ratings
47.67Average Price Target
The highest estimate is 60.00.
From 6 ratings within the last 6 months. This is not an investment recommendation.
From 6 ratings within the last 6 months. This is not an investment recommendation.
Buy 67%
Hold 33%
Sell 0%
People Also Follow
This list is based on the watchlists of people on Stock Events who follow HRMY. It's not an investment recommendation.
Competitors
This list is an analysis based on recent market events. It's not an investment recommendation.
Jazz Pharmaceuticals
JAZZ
Mkt Cap15.87B
Axsome Therapeutics
AXSM
Mkt Cap10.42B
Teva- Pharmaceutical Industries
TEVA
Mkt Cap42.46B
Biogen
BIIB
Mkt Cap32.28B
Supernus Pharmaceuticals
SUPN
Mkt Cap2.54B
Palatin Technologies
PTN
Mkt Cap18.65M
About
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company has one reportable segment: rare neurological diseases. Its product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.
Show more...
CEO
Jeffrey Dayno
Employees
293
Country
United States
ISIN
US4131971040
Listings
0 Comments
Share your thoughts
FAQ
What is Harmony Biosciences stock price today?▼
The current price of HRMY is $42.25 USD — it has increased by +0.93% in the past 24 hours. Watch Harmony Biosciences stock price performance more closely on the chart.
What is Harmony Biosciences stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange Harmony Biosciences stocks are traded under the ticker HRMY.
Is Harmony Biosciences stock price growing?▼
HRMY stock has risen by +7.75% compared to the previous week, the month change is a +9.03% rise, over the last year Harmony Biosciences has showed a +17.39% increase.
What is Harmony Biosciences market cap?▼
Today Harmony Biosciences has the market capitalization of 2.46B
When is the next Harmony Biosciences earnings date?▼
Harmony Biosciences is going to release the next earnings report on November 03, 2026.
What were Harmony Biosciences earnings last quarter?▼
HRMY earnings for the last quarter are 1.28 USD per share, whereas the estimation was 0.96 USD resulting in a +33.84% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Harmony Biosciences revenue for the last year?▼
Harmony Biosciences revenue for the last year amounts to 868.45M USD.
What is Harmony Biosciences net income for the last year?▼
HRMY net income for the last year is 158.69M USD.
How many employees does Harmony Biosciences have?▼
As of September 06, 2026, the company has 293 employees.
In which sector is Harmony Biosciences located?▼
Harmony Biosciences operates in the Health & Wellness sector.
When did Harmony Biosciences complete a stock split?▼
Harmony Biosciences has not had any recent stock splits.
Where is Harmony Biosciences headquartered?▼
Harmony Biosciences is headquartered in PLYMOUTH MEETING, United States.